G
Genvax Technologies
A startup animal vaccine company
About Genvax Technologies
Genvax Technologies, Inc. is a pioneering animal vaccine startup based in Ames, Iowa. The company specializes in developing next-generation mRNA nanoparticle vaccines aimed at preventing and treating animal diseases. Genvax serves the veterinary and animal health markets, targeting livestock producers, veterinary clinics, and animal health organizations. The business model revolves around research and development, followed by commercialization of their proprietary vaccines. Revenue is generated through the sale of these vaccines to clients in the animal health industry. The company leverages the expertise of its founders, Joel Harris and Dr. Hank Harris, who previously built and sold Harrisvaccines to Merck Animal Health in 2015. Genvax is committed to innovation and rapid response to emerging animal health challenges, striving to make a lasting impact on global animal health.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Ames, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Foundation for Food and Agriculture Research
Ag Startup Engine
Iowa Corn Growers Association
Summit Ag
United Animal Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genvax Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genvax Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.